Spravato Billing Services: Complete 2026 Guide to Esketamine Treatment Reimbursement & Coding

The FDA first approved Spravato on March 5, 2019, for adults with treatment-resistant depression (TRD), as the FDA's REMS approval letter notes. TRD generally means major depressive disorder with an inadequate response to at least two oral antidepressants. Spravato is also approved for depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behavior.

In January 2025, the FDA approved Spravato as a standalone treatment for adults with TRD, according to Johnson & Johnson. Before that change, it had to be paired with an oral antidepressant. In the study behind that decision, 22.5% of patients reached remission by week 4, compared with 7.6% on placebo.

Three features shape billing more than anything else:

• Controlled substance. Esketamine is a Schedule III drug, so storage, inventory and audit scrutiny all increase.
• Supervised use only. Patients self-administer in a certified healthcare setting and never take a device home.
• Dose by device. Each device delivers 28 mg, so 56 mg uses two devices and 84 mg uses three.

A standard medication management visit produces one E/M code. A Spravato session produces a drug line, a supervision service and an observation period. Medicare wraps those into one code, while commercial payers want them billed separately.

The observation period is where most documentation fails. Patients must stay under healthcare provider monitoring for at least two hours after each dose. Payers expect timestamps that prove it, not a general statement that the patient was observed.

Controlled substance status adds a second layer. You need DEA registration, secure storage and disposal procedures. Some payers also review esketamine claims more closely than claims for other psychiatric drugs.

The Spravato REMS Program: What Billing Teams Must Know

REMS stands for Risk Evaluation and Mitigation Strategy. Because of sedation, dissociation, respiratory depression and misuse risks, Spravato is available only through this restricted program. The REMS has been updated several times, most recently in April 2026, so check the program website for current forms.

From a billing view, three REMS elements matter:

• Certified setting. Only certified healthcare settings can administer Spravato, and the prescriber must be enrolled.
• Patient enrollment. Each patient is enrolled before the first dose and receives an enrollment ID for the chart.
• Patient Monitoring Form. Staff complete it after every session, including vital signs and the time the patient was ready to leave.

The REMS Patient Monitoring Form asks for blood pressure before dosing, about 40 minutes after dosing, and before discharge. Build your observation template around those same checkpoints. If your chart matches the form, an auditor has nothing to reconcile.

The code you use depends on who pays. Medicare uses bundled G-codes. Medicaid and commercial payers use a drug code plus separate service codes.

Check the patient's primary insurance before choosing codes. A G-code sent to a commercial payer, or J0013 sent to Medicare, will not be paid.

J0013: The Permanent Esketamine Drug Code

J0013 ("Esketamine, nasal spray, 1 mg") took effect on January 1, 2026, as listed in the January 2026 HCPCS update. It replaced S0013, which was deleted on December 31, 2025. Claims that still carry S0013 for 2026 dates of service are likely to reject.

Units equal the total milligrams given. A 56 mg session is 56 units, and an 84 mg session is 84 units. Billing one unit, or the number of devices, underbills the drug badly.

J0013 is not payable by Medicare. It covers the drug only, so supervision and observation are billed with separate codes. There is no separate administration code for a self-administered nasal spray.

Payers moved to J0013 at different speeds in early 2026. Confirm that each plan's fee schedule and prior authorization records list J0013. Some plans may still need updates on their side.

G2082 and G2083: Medicare's Bundled Codes

Medicare pays for each session with one code that includes the drug, the E/M service, supervision and two hours of observation:

• G2082: established patient visit with up to 56 mg of esketamine, including 2 hours of post-dose observation.
• G2083: established patient visit with more than 56 mg of esketamine, including 2 hours of post-dose observation.

A 28 mg or 56 mg session is G2082. An 84 mg session is G2083. Bill one G-code per session, with no J0013 and no separate E/M on the same claim.

One limit is easy to miss. According to Janssen's coding guidance, the G-codes apply when the practice supplies the drug itself. If a specialty pharmacy supplies it instead, confirm with your Medicare Administrative Contractor (MAC) how to bill the visit.

Payment amounts vary by MAC and locality. Look up your own rate in the Medicare Physician Fee Schedule before projecting program revenue.

Billing Observation Time for Commercial and Medicaid Payers

Who is the payer?

Medicare

• Dose up to 56 mgG2082
• Dose more than 56 mgG2083

Drug + visit + 2-hour observation bundled

Medicaid or commercial

J0013 · units = mg

+ E/M
+ prolonged codes 99415/99416 per plan policy

Commercial claims are built from parts: J0013 for the drug, an E/M code for the provider's evaluation, and prolonged service codes for the observation time. Many plans publish their own rules, so read the policy before the first claim.

Plan guidance commonly points to these codes:

• E/M (99212 to 99215): the provider's evaluation, chosen by medical decision-making or total provider time.
• 99415 and 99416: prolonged clinical staff time under provider supervision, which fits most observation work.
• 99417: prolonged provider time, reported only with the highest-level E/M code when billing by time.

For example, Blue Cross Blue Shield of Michigan tells commercial providers to bill J0013 and add 99415 and 99416 for clinical staff time. Blue Cross VT publishes its own prolonged-service rules for the same visit. Other plans may not pay for observation time at all.

Whatever the plan allows, the record must show who observed the patient and for how long. Prolonged service codes depend on documented time, so missing timestamps mean missing payment.

Medicare covers Spravato when the patient meets the approved indication and the session follows REMS rules. The bundled G-code is meant to cover the drug, the visit and the observation together.

Two errors cause most Medicare rejections. The first is adding J0013 or an E/M code to a G-code claim. The second is choosing G2082 when the documented dose was 84 mg.

Route Medicare claims to a G-code-only template and commercial claims to a J0013 template. If your system cannot do that automatically, add a payer check to the charge entry step.

Prior authorization is the most common reason Spravato claims fail. Every plan has its own form, its own definition of an adequate antidepressant trial, and its own renewal schedule.

A strong request lists each failed antidepressant with drug name, dose, duration and response. A note that only says "multiple medication trials" usually comes back with a request for details. Treatment then waits.

Most plans approve an initial induction period first. Continued treatment needs a new approval that shows improvement. Standardized depression scales such as the PHQ-9 or MADRS, recorded at baseline and during treatment, give the plan that evidence.

Since January 2025, Spravato can be used with or without an oral antidepressant for TRD. Some plan policies may not reflect the change yet, so check whether a plan still requires a concurrent oral antidepressant.

Renewals matter as much as first approvals. A dose given after an approval expires is usually unpaid. Set a reminder 30 days before each expiry date so there is time to submit and follow up.

Practices that need help with these renewals often use dedicated behavioral health billing services to track them.

Most Spravato denials come from a short list of preventable mistakes:

• Missing or expired prior authorization. Treatment started before approval, or a renewal was not filed in time.
• Deleted code. S0013 billed for a 2026 date of service instead of J0013.
• Unit mismatch. J0013 units that do not equal the milligrams given.
• Wrong pathway. A G-code sent to a commercial plan, or J0013 sent to Medicare.
• Thin observation notes. No start time, end time or vital signs.

Each one is easier to stop before submission than to appeal afterward. Practices without a dedicated workflow often lean on outside mental health billing support for this reason.

REMS Documentation Gaps and Post-Payment Risk

What every observation note needs

• Dose in mg
• Dose time
• Observation start and end
• Blood pressure before dosing
• Blood pressure about 40 minutes after dosing
• Blood pressure before discharge
• Adverse events
• Discharge readiness
• Patient Monitoring Form completed

Payers can review Spravato claims months after paying them. If the chart does not support the two-hour observation, the plan may recover the payment. Repeated REMS problems can also put the setting's certification at risk.

The fix is a structured observation template. It should capture dose time, observation start and end, the REMS vital sign checkpoints, any adverse events, and discharge readiness. Staff should complete the Patient Monitoring Form on the day of the session.

A short monthly chart review catches gaps early. If a chart does not match the claim, correct the documentation before the claim goes out.

A billing team that works with Spravato regularly builds checks into each step, instead of fixing problems after denials arrive.

• REMS verification. Confirm the setting, prescriber and patient enrollments are active before each scheduled dose.
• Payer policy tracking. Watch for changes such as the J0013 transition and update claim templates the same week.
• Unit checks. Compare the documented milligrams with the units on the claim and hold any mismatch.
• Pre-submission review. Hold claims whose observation notes lack timestamps or vital signs.
• Targeted appeals. Answer denials with the patient's treatment history, the plan's own policy language and the approved indication.

Run this list before each session and again before each claim.

1. Check REMS status. Setting, prescriber and patient enrollments are all active.
2. Confirm prior authorization. Record the number, start date and end date in the billing system.
3. Pick the payer pathway. Medicare gets G2082 or G2083; Medicaid and commercial get J0013 plus service codes.
4. Document the dose in milligrams. The note states the exact milligrams given, not just device count.
5. Match units to milligrams. J0013 units equal the milligrams documented in the note.
6. Timestamp the observation. Record start, end, and the REMS vital sign checkpoints.
7. Complete the Patient Monitoring Form. Finish it after every session and file a copy in the chart.
8. Attach records when the plan asks. Some plans want the note and approval letter with the claim.
9. Track renewal dates. Start each reauthorization 30 days before the current one ends.
10. Appeal quickly and specifically. Cite the record and the plan's own policy, within the plan's appeal deadline.

Nevada Med Billing works with behavioral health practices that want Spravato billing handled as its own workflow. We set up separate claim templates for Medicare and non-Medicare payers, so the right codes follow the patient's coverage.

Our team tracks prior authorizations and renewal dates, checks units against the documented dose, and reviews observation notes before claims go out. When a denial arrives, we compare the chart with the plan's policy and appeal with the specific evidence the plan asked for.

For practices starting a new program, we review documentation templates and train staff on billing-ready charting. Learn more about our behavioral health billing services.